Extended Follow-Up for Participants in VRC HIV-1 Recombinant Adenovirus-5 Vector Vaccine Studies in Uganda.
Phase of Trial: Phase IV
Latest Information Update: 24 Feb 2015
At a glance
- Drugs VRC-HIVADV014-00-VP (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Nov 2011 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Sep 2011 Actual initiation date (Jul 2010) added as reported by ClinicalTrials.gov.